SCHEMBL4175037

SCHEMBL4175037

O=C(c1csc(NS(=O)(=O)c2ccccc2)n1)N1CCCC1Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD5 Q86SK9 2/20 0.53
TRPC3 Q13507 3/20 0.44
TRPC6 Q9Y210 3/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
TRPA1 O75762 1/20 0.42
CACNA1C Q13936 1/20 0.42
SCN5A Q14524 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
TRPV4 Q9HBA0 1/20 0.42
SCN9A Q15858 2/20 0.42
DAGLA Q9Y4D2 4/20 0.41
ABHD6 Q9BV23 3/20 0.41
HSD11B1 P28845 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176246 0.91 DPP4 (0.49) SCD5SCN9AKDM1AHCRTR1HCRTR2
SCHEMBL4166426 0.88 DPP4 (0.47) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4180040 0.85 TRPC3 (0.44) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4184719 0.85 ALDH1A1 (0.40) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4172971 0.84 TRPC3 (0.44) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4172599 0.84 TRPC3 (0.61) SCD5TRPC3TRPC6TRPA1CACNA1C
SCHEMBL4183923 0.84 TRPC3 (0.47) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4180047 0.82 TRPC3 (0.47) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4176363 0.82 TACR3 (0.47) SCD5TRPC3TRPC6ALDH1A1CYP2C9
SCHEMBL4165105 0.81 TRPC3 (0.66) SCD5TRPC3TRPC6ALDH1A1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCD5 1301/4885TRPC3 57/4885TRPC6 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.